Iron deficiency either absolute or functional, is an independent predictor of all cause and cardiovascular mortality and a major contributor to exercise intolerance, even in absence of anemia. Correcting these comorbidities is attractive and novel therapies targets to improve outcomes. At present, IV iron is preferred route for treatment in such patients. Most studies have used IV iron sucrose (max dose of 200mg/setting) or ferric carboxymaltose (max dose of 1000mg/setting). Our study determines advantage of IV iron carboxymaltose over iron sucrose by being cost effective, requiring fewer injections, lesser duration of hospital stay with minimum adverse effect and equivocal improvement in quality of life and hematological profile in patients with heart failure with either preserved or reduced ejection fraction.